Consensus Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.7741 USD -0.78% Intraday chart for Seres Therapeutics, Inc. -2.67% -44.71%

Evolution of the average Target Price on Seres Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

047ea8c19e.CWpoUbnTeDD87LS8wwUApG5U0rr5-oAf5Zq7reOxLGg.cFkaEv-DIACGptfeqEpIwAQmi_vMktlYtqzu_JX1Z1x8XB4E86EtXsqB2w~20e14e476176d9fe68aab40099c1a332
Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating MT
Chardan Cuts Price Target on Seres Therapeutics to $8 From $10 on Higher Expected Sharecount Dilution, Keeps Buy Rating MT
Oppenheimer Trims Seres Therapeutics Price Target to $9 From $10, Maintains Outperform Rating MT
Goldman Sachs Adjusts Price Target on Seres Therapeutics to $1.25 From $4, Maintains Sell Rating MT
Oppenheimer Adjusts Seres Therapeutics Price Target to $10 From $12, Maintains Outperform Rating MT
Chardan Cuts Price Target on Seres Therapeutics to $10 From $12, Keeps Buy Rating MT
JPMorgan Starts Seres Therapeutics at Neutral MT
Canaccord Genuity Adjusts Price Target on Seres Therapeutics to $15 From $11, Maintains Buy Rating MT
Canaccord Genuity Lowers Price Target on Seres Therapeutics to $11 From $17, Maintains Buy Rating MT
Piper Sandler Adjusts Price Target on Seres Therapeutics to $9 From $7, Reiterates Overweight Rating MT
Chardan Capital Lowers Seres Therapeutics Price Target to $12 From $16, Maintains Buy Rating MT
Oppenheimer Adjusts Seres Therapeutics' Price Target to $12 From $13, Maintains Outperform Rating MT
Piper Sandler Lowers Seres Therapeutics' to $7 From $32, Overweight Rating Kept MT
Oppenheimer Adjusts Seres Therapeutics Price Target to $13 From $16, Maintains Outperform Rating MT
SERES THERAPEUTICS : Oppenheimer Adjusts Seres Therapeutics PT to $18 From $36, Maintains Outperform Rating MT
SERES THERAPEUTICS : Chardan Adjusts Price Target on Seres Therapeutics to $16 From $30 After Drug Disappoints in Study, Maintains Buy Rating MT
SERES THERAPEUTICS : Canaccord Genuity Adjusts Seres Therapeutics' Price Target to $29 From $42, Maintains Buy Rating MT
SERES THERAPEUTICS : HC Wainwright Adjusts Seres Therapeutics' Price Target to $25 From $46, Keeps Buy Rating MT
SERES THERAPEUTICS : Goldman Sachs Cuts Seres Therapeutics to Sell From Neutral, Price Target to $7 From $24 MT
SERES THERAPEUTICS : Piper Sandler Adjusts Price Target on Seres Therapeutics to $40 From $47, Maintains Overweight Rating MT
SERES THERAPEUTICS : Goldman Sachs Assumes Seres Therapeutics at Neutral with $24 Price Target MT
SERES THERAPEUTICS : Oppenheimer Adjusts Seres Therapeutics PT to $36 From $38, Maintains Outperform Rating MT
SERES THERAPEUTICS : HC Wainwright Adjusts Seres Therapeutics' Price Target to $46 From $41, Maintains Buy Rating MT
SERES THERAPEUTICS : Chardan Upgrades Seres Therapeutics to Buy From Neutral, Adjusts Price Target to $30 From $27.50 MT
SERES THERAPEUTICS : JMP Securities Starts Seres Therapeutics at Market Perform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.7741 USD
Average target price
7.22 USD
Spread / Average Target
+832.70%
High Price Target
15 USD
Spread / Highest target
+1,837.73%
Low Price Target
1.1 USD
Spread / Lowest Target
+42.10%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Seres Therapeutics, Inc.

Oppenheimer
Chardan Research
Goldman Sachs
JPMorgan Chase
Canaccord Genuity
Piper Sandler
HC Wainwright
Chardan
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings